Protalix BioTherapeutics
PLX
83 hedge funds and large institutions have $26.8M invested in Protalix BioTherapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
32% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 22
8% more funds holding
Funds holding: 77 → 83 (+6)
1.07% more ownership
Funds ownership: 17.47% → 18.53% (+1.1%)
13% less capital invested
Capital invested by funds: $30.9M → $26.8M (-$4.08M)
38% less call options, than puts
Call options by funds: $31K | Put options by funds: $50K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$593K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$573K |
| 3 |
RRA
Round Rock Advisors
Wilton,
Connecticut
|
+$317K |
| 4 |
Goldman Sachs
New York
|
+$229K |
| 5 |
BlackRock
New York
|
+$196K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$344K |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$209K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$132K |
| 4 |
Renaissance Technologies
New York
|
-$107K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$105K |
PLX Hedge Fund Activity: Q4 2025 in Review
83 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2025, worth a combined $26.8M — down 13% from $30.9M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PLX positions and 5 closed out — a net gain of 7 holders — while 29 added to existing stakes and 22 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $593K. The largest seller was Connor, Clark & Lunn Investment Management (CC&L), cutting an estimated $344K.
- 83 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2025, up from 77 in Q3 2025.
- Funds reported $26.8M of Protalix BioTherapeutics stock for Q4 2025, down 13% quarter-over-quarter.
- 12 funds opened new Protalix BioTherapeutics positions in Q4 2025 and 5 closed out, a net change of +7 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2025 was Jane Street, an estimated $593K added.
- The largest Protalix BioTherapeutics seller in Q4 2025 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $344K sold.
Based on aggregated 13F filings for Q4 2025.